Skip to main content

LianBio (LIAN)

NASDAQ: LIAN · IEX Real-Time Price · USD
10.08 -0.23 (-2.23%)
Dec 3, 2021 4:00 PM EST - Market closed
Market Cap1.06B
Revenue (ttm)n/a
Net Income (ttm)-294.97M
Shares Out105.26M
EPS (ttm)-2.80
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume590,570
Open10.31
Previous Close10.31
Day's Range8.74 - 10.31
52-Week Range8.74 - 16.37
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About LIAN

LianBio is a global, science-driven biopharmaceutical company dedicated to developing and commercializing innovative medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets. We have purposefully designed our organization to successfully execute on our vision by identifying, sourcing, developing and commercializing product candidates and partnering with highly innovative biopharmaceutical companies around the world. We are establishing an international infrastructure...

IndustryBiotechnology
IPO DateNov 1, 2021
CEOYizhe Wang, Ph.D.
Employees69
Stock ExchangeNASDAQ
Ticker SymbolLIAN
Full Company Profile

News

LianBio Announces Pricing of Initial Public Offering

SHANGHAI, China and PRINCETON, N.J., Oct. 31, 2021 (GLOBE NEWSWIRE) -- LianBio, a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, tod...

1 month ago - GlobeNewsWire

LianBio Announces Launch of Initial Public Offering

LianBio, a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the launch of its proposed initial public offering of its ...

1 month ago - Business Wire

LianBio IPO Registration Document (S-1)

LianBio has filed to go public with an IPO on the NASDAQ.

2 months ago - SEC